Cortexin
Cortexin is a polypeptide complex derived from bovine cerebral cortex, widely used in Russian and Eastern European clinical medicine for neuroprotection, stroke recovery, and cognitive enhancement. It contains a mixture of low-molecular-weight neuropeptides that cross the blood-brain barrier and exert broad neurotrophic and neuroprotective effects.
Common Dosage
10mg IM or subcutaneous daily for 10 days per cycle
Category
Nootropic
- Neuroprotection and neuronal survival
- Stroke and TBI recovery support
- Cognitive function improvement
- BDNF and NGF upregulation
- Antioxidant effects in neuronal tissue
- Seizure threshold elevation
Cortexin is a polypeptide complex first developed in Russia in the 1980s at the Institute of Experimental Medicine in Leningrad (now St. Petersburg). It belongs to the class of 'peptide bioregulators' — an approach to medicine pioneered by Vladimir Khavinson and colleagues, based on the hypothesis that organ-specific low-molecular-weight peptides extracted from animal tissue can restore and normalize the function of the corresponding human organ. Cortexin is extracted from bovine or porcine cerebral cortex and contains a complex mixture of peptides with molecular weights under 10,000 Da — small enough to potentially cross the blood-brain barrier. It has been registered as a pharmaceutical drug in Russia, Ukraine, and several other post-Soviet countries since the 1990s and is widely prescribed in clinical neurology for stroke, traumatic brain injury, and age-related cognitive decline. Tens of thousands of patients have received Cortexin in formal clinical trials and standard clinical practice across Eastern Europe.
Cortexin's mechanism is complex and incompletely characterized, reflecting its nature as a multi-peptide mixture rather than a single molecular entity. Documented effects include: upregulation of BDNF (brain-derived neurotrophic factor) and NGF (nerve growth factor) in neuronal tissue; activation of GABA-ergic inhibitory pathways that reduce excitotoxicity; inhibition of lipid peroxidation and oxidative stress in neural tissue; regulation of serotonin and dopamine metabolism; and modulation of DNA repair mechanisms in neurons. Individual peptides within the mixture have been identified as acting on different targets — some mimicking endogenous neurotrophins, others reducing neuroinflammation via cytokine suppression. The aggregate effect is broadly neuroprotective across multiple parallel mechanisms.
- Ischemic and hemorrhagic stroke recovery — the most studied and widely used clinical application
- Traumatic brain injury (TBI) — acute neuroprotection and long-term functional recovery
- Perinatal brain injury and neonatal encephalopathy — common use in Russian pediatric neurology
- Age-related cognitive decline and vascular dementia
- Epilepsy — seizure threshold elevation and neuroprotection adjunct to anticonvulsants
- Cerebral palsy — improving cognitive and motor outcomes in affected children
- Parkinson's disease — neuroprotective adjunct in early-stage research
- Depression and anxiety — serotonin/dopamine regulatory effects in clinical practice
Stroke Recovery Clinical Trials
Multiple Russian clinical trials enrolling stroke patients found that Cortexin administered within 6 hours of ischemic stroke onset significantly improved neurological deficit scores (NIHSS, Barthel Index) at 10 and 21 days compared to standard care alone. A meta-analysis of these trials showed consistent improvement across motor, cognitive, and functional outcome measures, with a favorable safety profile.
Pediatric Neurological Outcomes
Cortexin is extensively used in Russian pediatric neurology for perinatal encephalopathy. Controlled trials in neonates with hypoxic-ischemic encephalopathy showed improved psychomotor development scores at 6-month and 12-month follow-up compared to standard care, with particular benefit in language acquisition and motor milestone achievement.
Cognitive Enhancement Research
Studies in healthy adults and those with age-related cognitive decline show improvements in memory consolidation, attention span, and processing speed after 10-day Cortexin cycles. BDNF levels increase measurably after treatment, providing a mechanistic correlate for the observed cognitive effects.
- Animal-derived peptide complex — bovine or porcine sourcing raises concerns in individuals with relevant dietary, religious, or prion-disease risk considerations
- Most clinical evidence comes from Russian studies with varying methodological quality — rigorous Western randomized controlled trial data is limited
- Complex mixture with incompletely characterized active components — precise mechanisms and dose-response relationships are difficult to establish
- Regulatory status: not approved by FDA, EMA, or equivalent Western regulatory bodies for any indication
- Injection site reactions — delivered intramuscularly or subcutaneously, with localized discomfort common
- Batch-to-batch variability in multi-peptide natural extracts is greater than for synthetic single-peptide compounds
- Injection site reaction
- Mild dizziness (rare)
- Transient fatigue during initial dosing